
|Videos|April 26, 2022
EGFR Exon 20–Positive NSCLC: Future Directions in Care
Author(s)Zofia Piotrowska, MD, MHS
Before closing out her discussion on novel therapy for EGFR exon 20–positive NSCLC, Zofia Piotrowska, MD, shares her hopes for future developments in care.
Advertisement
Case: A 59-Year-Old Female with Lung Cancer
Initial presentation
- BC is a 59 y/o Asian female who presents to her physician complaining of shortness of breath, fatigue, and persistent right- sided neck pain.
- BC believes she is experiencing neck pain because of her new sleeping pillow.
- Since her last examination 6 months ago, BC has lost close to 10 lbs. BC has not changed her eating habits or style.
- PMH: Hypercholesterolemia (controlled)
- SMH: no history of smoking; drinks socially
- FH: she lives with her partner and 2 dogs; mother passed away from ovarian cancer 3 years ago.
- PE: LLL auscultation reveals decreased breath sounds visible bruising
Clinical workup
- Current Labs:
- CBC panel: Normal
- Liver function/Renal function: Normal
- CT Chest: LLL primary, mediastinal LNs; bone metastases
- Diagnosis: Stage IV adenocarcinoma
- MRI brain is negative for brain metastases
- CT scan of abdomen and pelvis shows additional bone metastases
- Weight: 120 lbs (54.5 kg)
- Biopsy of mediastinal lymph nodes shows stage 4 lung adenocarcinoma
- PD-L1 55%
Treatment
- NGS has been ordered and the results are pending.
- Patient initiated on a chemotherapy doublet.
Advertisement
Related to this article

US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.

Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.

David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.

The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
IMS 2026 Day 3 Recap: Etentamig Outperforms Standard Therapy in RRMM Trial
5

